SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to mixed reactions following its earnings release and subsequent stock movement, with community members debating whether the stock is overvalued. A significant point of discussion is Michael Burry's reported short position against the company. Despite positive earnings news, the stock's high valuation and potential AI bubble concerns are driving bearish sentiment.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is gaining attention, particularly within communities focused on the Solana ecosystem, with some users expressing bullish sentiment while others discuss challenges. The community emphasizes a shared vision and encourages building together, fostering a sense of unity despite market conditions.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors assess the implications of Q3 earnings, which included a massive EPS beat, even as some profit forecasts fell slightly short. The community is actively discussing the company's growth in bookings and trips, particularly the impact of Uber One memberships, while also debating whether the stock is currently undervalued given its market dominance and future potential in autonomous vehicles. Short-term manipulation and broader market conditions are also being considered as factors influencing the stock's price movement.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about a confirmatory trial and its potential impact on existing PMO therapies, which are facing scrutiny, while Elevidys sales remain a key focus. The community is weighing the implications for future revenue and potential FDA actions, with some speculating about a possible Roche buyout amid the uncertainty. Discussions also involve management's handling of recent data releases and their overall strategy.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin's recent price volatility has the community debating whether a longer-term correction is underway. Some traders believe institutions are strategically selling off, while others see the dip as a bear trap before a potential rally toward previous highs. Discussions also involve the influence of broader market factors, such as the Nasdaq and potential government actions, on Bitcoin's price.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid discussions about its potential as a leading privacy coin and a hedge against Bitcoin's volatility, as some community members suggest it could reach new all-time highs. The conversations also highlight its upcoming anniversary, possibly leading to increased attention and speculation about future developments. Simultaneously, some traders are noting its overbought conditions and anticipating a potential pullback.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as community members assess the implications of recent earnings, raised guidance, and a notable dividend yield. Discussions include whether the market is undervaluing the stock, and speculation on potential acquisitions in the competitive obesity therapeutics market with some suggesting it may be a good long-term hold. Additionally, Michael Burry's position in PFE calls is generating buzz among investors.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst mixed sentiment, with some traders citing potential partnerships and real-world utility while others express concerns about its price action and long-term viability. Community discussions revolve around identifying key resistance levels and whether the current market cap is justified. Speculation about future developments and potential catalysts continues to fuel the conversation.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending as optimism grows around potential FDA approvals and encouraging clinical trial data, particularly in KRAS-mutant cancers. The community is actively discussing long-term prospects, potential buyouts, and comparisons to competitors in the oncology space. Bullish sentiment is fueled by expectations of significant valuation increases and potential for a short squeeze.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as investors discuss the company's recent earnings report, which revealed revenue growth and cash flow positivity. Community members are debating whether the current valuation is justified amidst competition and broader market conditions. Some are optimistic about the company's future prospects, citing potential AI modeling and strategic partnerships with established brands.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ETF Areas to Buy on Fed Cuts and Trade Truce Optimism

Fed turns dovish and trade tensions ease. Amid this scenario, tech & growth ETFs could soar along with some other areas. Watch SMH, QQQ, SPYG & IWO as markets may be up for a renewed rally.

<ul class="summary-bullets"><li>ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.</li><li>Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.&nbsp;</li><li>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome.&nbsp; &nbsp;</li></ul>Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-phase-2-clinical">said.</a>No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.<h2 class="st-heading-2">Plans Ahead</h2>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.ALDX stock is down by 0.5% this year and by about 12% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slumped-nearly-19-percent-in-eu-in-september-despite-rising-ev-demand/cLGjW7LR3HL">Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 

Equity

<ul class="summary-bullets"><li>The company announced the exercise of existing warrants held by an institutional investor.</li><li>The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.&nbsp;</li><li>The transaction is expected to close on or about October 28, the company said.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 6% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.The warrants were previously issued in March and August 2024, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-31-Million-in-Gross-Proceeds/default.aspx">said</a>. The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.The new warrants will be exercisable immediately and will expire five years from the date of issuance, the company said.The closing of the translation is expected to occur on or about October 28, it added.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SLS"> SLS stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user recommended holding the stock, opining that it will now go higher.<stembedurl>https://stocktwits.com/Kevoo/message/633843705</stembedurl>Another dismissed concerns of dilution, terming the warrant exercise a “not that big deal.”<stembedurl>https://stocktwits.com/Risulom/message/633841655</stembedurl> In September, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-in-spotlight-after-institutional-investor-exercises-existing-warrants/chwNYhvRdvv">announced</a> that an institutional investor had exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025, the company then said.SLS stock is up by 80% this year and by about 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is SELLAS Life Sciences Stock Falling Today?

Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 5% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.

Why Is SELLAS Life Sciences (SLS) Stock Falling Today?

Tvardi Therapeutics (TVRD) on Monday said that its TTI-101, being evaluated in idiopathic pulmonary fibrosis (IPF), showed no benefit over placebo in a mid-stage trial.The trial was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function in patients with IPF. Idiopathic Pulmonary Fibrosis is a progressive lung disease where lung tissue thickens and scars, making it difficult to breathe. However, the study did not meet its goals, and no statistically significant differences between placebo and treatment arms were observed after a preliminary review of exploratory efficacy, it said.Shares of the company plummeted 87% in Monday’s pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TVRD">TVRD stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.Tvardi said that preliminary data showed that patients’ baseline characteristics were mostly similar across treatment arms, including those who received the two doses of TTI-101 or those who received a placebo in the trial. Furthermore, lower discontinuation rates were observed in the placebo group compared to the therapy-treated arms, it added.The company also noted that patients who demonstrated changes in the lung’s Forced Vital Capacity (FVC) were 41% for the placebo, and 39% and 44% for the 400mg and 800mg TTI-101-treated arms, respectively.“In the aggregate, we did not observe a benefit of TTI-101 treatment in this IPF study. The limited data set, high variability within treatment arms, and unexpected performance of the placebo arm make it difficult to provide more definitive conclusions at this time,” CEO Imran Alibhai said.The CEO added that the company is now conducting additional analyses to understand the trial findings further. He also noted that the company is on track to report preliminary data from the mid-stage trial of TTI-101 in hepatocellular carcinoma.TVRD stock has risen about 127% this year and more than quadrupled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-commences-production-ramp-up-at-shanghai-gigafactory/ch6SiqpR3kW">Tesla Reportedly Commences Production Ramp-Up At Its Shanghai Gigafactory</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?

The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review of exploratory efficacy. 

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

SoundHound AI, Inc.(SOUN) on Wednesday said it has teamed up with Apivia Courtage, part of the AEMA Group, to bring advanced AI agents into the insurer’s contact centers using SoundHound’s Amelia 7 platform.Under this collaboration, Apivia Courtage will roll out Amelia 7, an AI agent system designed to act autonomously, as a key component of its digital overhaul strategy, building on the success with SoundHound’s platform, which resulted in a 20% productivity boost.<a href="https://stocktwits.com/symbol/SOUN">SoundHound AI stock</a> traded over 8% higher on Wednesday afternoon. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘normal message volume levels.<figure class="image"><img style="aspect-ratio:925/100;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_08_130638_png_e64e4f8927.webp" alt="SOUN’s Sentiment Meter and Message Volume as of 12:45 p.m. ET on Oct. 8, 2025 | Source: Stocktwits" width="925" height="100"><figcaption>SOUN’s Sentiment Meter and Message Volume as of 12:45 p.m. ET on Oct. 8, 2025 | Source: Stocktwits</figcaption></figure>The stock saw a 161% increase in user message count in the last month, as per platform data. A Stocktwits user expressed confidence in the partnership, stating that the company is a “huge player” in France.<stembedurl>https://stocktwits.com/Ibiolegends/message/631509252</stembedurl>Amelia’s architecture blends large language models’ reasoning and planning with structured rule‑driven workflows. It also supports escalation to humans when needed. The AI agents operate across multiple channels, including voice, chat, and text.With Amelia 7’s “agentic” capabilities, Apivia aims to let customers self‑serve on more types of inquiries without human intervention. The AI agents will interpret multiple intents in a single interaction, carry out tasks like identity verification via one-time passwords, answer policy questions, update contact details, compute the financial impact of contract changes, and initiate quotes or book meetings with advisors.Since 2023, the two companies have worked together to integrate AI agents alongside human staff at Apivia’s call centers. SoundHound AI stock has gained over 317% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-hits-all-time-high-after-nvidia-ceo-jensen-huang-calls-offering-10-percent-stake-to-open-ai-clever/ch6EpkDR30b">AMD Hits All-Time High After Nvidia CEO Jensen Huang Calls Offering 10% Stake To OpenAI ‘Clever’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Amelia logo is being displayed on a mobile phone screen in front of a monitor displaying SoundHoundAI logo in Ankara, Turkiye on August 27, 2024. 

SoundHound, Apivia Deploy Agentic AI For Insurance Contact Centers: Retail Sentiment Jumps

Under the partnership, Apivia Courtage will roll out Amelia 7, an AI agent system designed to act autonomously, building on earlier success where SoundHound’s platform boosted productivity by 20%.

Small-Cap Wins in Q3: Top-Performing ETFs in Focus 

Small caps staged a comeback in Q3, with ETFs like FESM, RZV, FYX, VTWV, JSML, IWO topping gains. While there are certain tariff risks, the Fed's rate cut potential is a plus. 

SoundHound AI Inc. (SOUN) stock was in the spotlight on Monday morning after the shares received an upgrade from Ladenburg Thalmann, which raised its rating to ‘Buy’ from ‘Neutral’ and raised the price target to $16 from $9.&nbsp;The brokerage cited strong second-quarter (Q2) results and successful execution on large enterprise deals as key reasons for its upgrade, as per TheFly.&nbsp;<a href="https://stocktwits.com/symbol/SOUN">SoundHound AI stock</a> shot up over 13% on Monday morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.<figure class="image"><img style="aspect-ratio:955/110;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_095242_png_df04a03eb4.webp" alt="SOUN’s Sentiment Meter and Message Volume as of 09:45 a.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="955" height="110"><figcaption>SOUN’s Sentiment Meter and Message Volume as of 09:45 a.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced a 176% increase in user message count over 24 hours, as of Monday morning. A Stocktwits user said the business has ‘great demand’.<stembedurl>https://stocktwits.com/Tekoa/message/624580522</stembedurl>Another user commended the Q2 earnings print.<stembedurl>https://stocktwits.com/paaps/message/624567480</stembedurl>Ladenburg sees sales growth momentum as justifying its increased spending levels. The brokerage remains optimistic about the opportunity in voice-based artificial intelligence, identifying it as one of the most promising early-use cases in the AI space.&nbsp;The firm believes SoundHound’s products cater to businesses that want to integrate AI-driven voice features into their operations.The company’s Q2 revenue jumped 217% year-on-year (YoY) to $42.7 million, beating the analysts’ consensus estimate of $32.88 million, as per Fiscal AI data. The adjusted loss per share of $0.03 came in wider than the consensus estimate of a loss of $0.01.The company raised its FY2025 revenue guidance to a range of $160 million and $178 million. On August 7, SoundHound launched Vision AI, a visual recognition engine built directly into its voice-centric platform.SoundHound AI stock has lost over 24% year-to-date and has gained over 190% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/black-monday-for-monday-dot-com-stock/chruzItRdeT">Black Monday For Monday.Com Stock? Here’s What Co-CEO Roy Mann Said About Google Algorithm Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Binary code displayed on a laptop screen displayed on a laptop screen and SoundHound AI logo displayed on a phone screen are seen in this illustration photo taken in Krakow, Poland on August 8, 2025. 

SoundHound Stock Surged 13% Today – And Ladenburg Thalmann Has A New Price Target 

The firm cited strong second-quarter results and successful execution on large enterprise deals as key reasons for the upgrade.

SoundHound stock was the top-trending equity ticker on Stocktwits late Thursday as retail investors reacted to the conversational artificial intelligence (AI) company announcing a beat-and-raise quarter.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SOUN">SoundHound stock</a> turned to ‘extremely bullish’ (88/100) by late Thursday from ‘neutral’ a day ago. The message volume also picked up pace to ‘extremely high’ levels.&nbsp;The 24-hour message volume change leading up to late Thursday was about 500%.<figure class="image"><img style="aspect-ratio:618/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_07_at_10_15_05_PM_png_18725d4ece.webp" alt="Screenshot 2025-08-07 at 10.15.05 PM.png" width="618" height="54"><figcaption>SOUN sentiment and message volume as of 10:15 p.m. ET, Aug. 7 | source: Stocktwits</figcaption></figure>Santa Clara, California-based SoundHound reported a loss of $0.03 per share on an adjusted basis for the second quarter of the fiscal year 2025, narrower than the year-ago loss of $0.04 and the Factset-compiled consensus of $0.05 per share.Revenue climbed 217% year-over-year to $42.68 million, sharply higher than the $32.9-million consensus estimate.Co-founder and CEO Keyvan Mohajer said, “In SoundHound’s strongest ever quarter, many of our previous strategic moves delivered high-impact results with growth across every business unit.”“We realized significant new wins as well as cross-sell deals, demonstrating the incredible opportunity we predicted with our 2024 acquisitions.”SoundHound ended the quarter with cash and cash equivalents of $230 million as of June 30 and boasted of no debt on its balance sheet.The company raised its full-year revenue outlook to a range of $160 million to $178 million from a range of $157 million to $177 million.Underlining the massive potential for conversational AI,&nbsp;Mark Zuckerberg’s Meta&nbsp;Platforms Inc.&nbsp;made its second voice AI startup acquisition, WaveForms, according to a report by The Information, just a month after purchasing PlayAI.Commenting on Stocktwits, a bullish watcher&nbsp;noted that a majority of the volume in SoundHound stock over the past week was from dark pool or off-exchange transactions. They also noted that the short interest was high,&nbsp;which they considered a positive for the underlying stock.<stembedurl>https://stocktwits.com/notihimself/message/624253898</stembedurl>The short interest in the stock is currently at 30.32%, according to Koyfing, and it has remained above this level since late May.Another user&nbsp;considered the stock price to be too low, noting that it was trading at double the current levels at the start of the year and that the earnings report indicated the company was performing well.<stembedurl>https://stocktwits.com/DakotaDan1/message/624252035</stembedurl>SoundHound stock has grossly underperformed the broader market, having lost 46% this year. In overnight trading, the stock was up over 14%, and if&nbsp;gains carry over into Friday’s session, it&nbsp;would mark its best session since late May, according to Koyfin data.The Koyfin-compiled average analysts’ price target for the stock is $11.81, implying upside potential of over 10%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-stock-marks-worst-day-in-25-years-as-weight-loss-pill-data-disappoints-analysts-divided-but-retail-bets-on-rebound/chrVvOxRd3V">Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound</a>

SoundHound Retail Traders Brace For More Stock Gains After Voice AI Player Reports ‘Strongest-Ever Quarter’

The company’s Q2 revenue soared 217% year-over-year to $42.68 million, sharply higher than the $32.9-million consensus estimate.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 Growth ETF

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

IWO
iShares Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWO News

IWOiShares Russell 2000 Growth ETF